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Reduces Shocks in Primary Prevention Patients
Results From the PREPARE
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Objectives Our purpose was to demonstrate that strategically chosen implantable cardioverter-defibrillator (ICD) ventricular
tachycardia (VT) or ventricular fibrillation (VF) detection and therapy parameters can reduce the combined incidence
of device-delivered shocks, arrhythmic syncope, and untreated sustained symptomatic VT/VF (morbidity index).
Background Strategically chosen ICD VT/VF detection and therapy parameters have been shown in previous studies to re-
duce the number of shocked episodes. In the PREPARE (Primary Prevention Parameters Evaluation) study, these
prior strategies were combined with additional strategies specific to primary prevention patients.
Methods The PREPARE study was a prospective, cohort-controlled study that analyzed 700 patients (biventricular [Bi-V]
ICD and non–Bi-V ICD) with primary prevention indications for an ICD from 38 centers followed for 1 year. VT/VF
was detected for rates 182 beats/min that were maintained for at least 30 of 40 beats. Antitachycardia pac-
ing was programmed as the first therapy for regular rhythms with rates of 182 to 250 beats/min, and
supraventricular tachycardia discriminators were used for rhythms 200 beats/min. The control cohort con-
sisted of 689 primary prevention patients from the EMPIRIC (Comparison of Empiric to Physician-Tailored Pro-
gramming of Implantable Cardioverter Defibrillators Trial) (non–Bi-V ICD, physician arm only) and MIRACLE ICD
(Multicenter InSync Implantable Cardioversion Defibrillation Randomized Clinical Evaluation) (Bi-V ICD) trials for
whom VT/VF detection and therapy programming were not controlled.
Results The PREPARE programming significantly reduced the morbidity index incidence density (0.26 events/patient-year for
PREPARE study patients vs. 0.69 control cohort, p 0.003). The PREPARE study patients were less likely to receive a
shock in the first year compared with control patients (9% vs. 17%, p 0.01). The incidence of untreated VT and
arrhythmic syncope was similar between the PREPARE study patients and the control cohort.
Conclusions Strategically chosen VT/VF detection and therapy parameters can safely reduce shocks and other morbidities
associated with ICD therapy in patients receiving an ICD for primary prevention indications. (PREPARE-Primary
Prevention Parameters Evaluation; NCT00279279) (J Am Coll Cardiol 2008;52:541–50) © 2008 by the
American College of Cardiology Foundation
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The PREPARE Study Versus Physician-Tailored Programming of ICDs August 12, 2008:541–50The effectiveness of implantable
cardioverter-defibrillator (ICD)
therapy at reducing mortality is
well documented, initially as sec-
ondary prevention after aborted
sudden cardiac death and more
recently in primary prevention
patients (1,2). However, the
mortality benefit comes at the
cost of some morbidity, includ-
ing the pain caused by defibril-
lating shocks, both appropriate
and inappropriate. Between 15%
to 25% of patients who receive
multiple shocks experience in-
creased anxiety and depression
and, therefore, have difficulty ad-
justing to life with an ICD (3,4).
n addition, a shock may be proarrhythmic (5). Therefore,
voidance of unnecessary shocks remains an important goal.
revious investigations have demonstrated substantial dif-
erences in frequency, rate, and mechanisms of tachycardia
bserved in patients with ICDs implanted for primary
ersus secondary prevention indications (6). The primary
revention patient population has been reported to have a
ower incidence of ventricular arrhythmias compared with
econdary prevention patients (6,7). Consequently, a higher
roportion of ICD therapies in primary prevention patients
ould be due to inappropriate detections and therapies
rimarily due to arrhythmias such as sinus tachycardia and
trial fibrillation (6,8).
The PainFREE RX II (Pacing Fast VT REduces Shock
hErapies) and EMPIRIC (Comparison of Empiric to
hysician-Tailored Programming of Implantable Cardio-
erter Defibrillators) trials demonstrated that specific ven-
ricular tachycardia (VT) and ventricular fibrillation (VF)
etection and therapy programming strategies reduced the
requency of shocked episodes (9,10). The use of detection
lgorithms designed to distinguish supraventricular and
entricular tachyarrhythmias and the use of antitachycardia
acing (ATP) to terminate rapid VTs have been reported to
e important components of programming strategies de-
igned to optimize ICD programming (11–14). The
MPIRIC and PainFREE RX II trials assessed ICD
etection and therapy strategies to safely reduce the mor-
idity associated with ICD shock in a patient population
hat included primary and secondary prevention patients
ith no indication for a biventricular (Bi-V) ICD device.
he purpose of the PREPARE (Primary Prevention Pa-
ameters Evaluation) study was to adapt these strategies
pecifically to primary prevention patients both with and
ithout Bi-V ICD indications. A treatment rate cutoff of
88 beats/min has been used to treat primary prevention
atients in several large trials (2,6,15). In the latter 2 studies,
nvestigators recommended a treatment cutoff between 170
Abbreviations
and Acronyms
ATP  antitachycardia
pacing
Bi-V  biventricular
CI  confidence interval
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
LVEF  left ventricular
ejection fraction
SVT  supraventricular
tachycardia
VF  ventricular fibrillation
VT  ventricular
tachycardiand 180 beats/min for primary prevention patients in order po reduce the proportion of inappropriate therapies while
till providing appropriate therapy. These recommendations
ere adopted for the PREPARE study, which used a rate
utoff of 182 beats/min.
ethods
atients. THE PREPARE STUDY COHORT. Details of the
REPARE study design have been previously reported
16). The PREPARE study was a prospective 38-center
tudy comprised of 700 patients without a history of
pontaneous sustained symptomatic VT or VF (primary
revention patients), who had an indication for a single
hamber, dual chamber, or Bi-V ICD.
nclusion criteria required:
Initial implantation for primary prevention ICD indica-
tions or
Prior ICD implantation within 6 months without sub-
sequent spontaneous VT/VF episodes
atients were excluded for:
History of spontaneous sustained symptomatic ventricu-
lar arrhythmias
An electrophysiology test in the past, with inducible
sustained VT 180 beats/min
Any ICD implanted 6 months before the study
An ICD implanted within the previous 6 months, with
subsequent history of a spontaneous episode of VT or VF
appropriately treated with either ATP or shock
atients were not excluded for a history of supraventricular
achycardia (SVT) or other nonventricular tachycardia or a
entricular fibrillation event. Enrollment was conducted
etween October 2003 and May 2005. The institutional
eview board at each center approved the study protocol,
nd written informed consent was obtained from each
atient.
ONTROL COHORT. The control cohort was a historical
ontrol group comprised of the entire subset of patients
rom the previously conducted MIRACLE ICD (Multi-
enter InSync Implantable Cardioversion Defibrillation
andomized Clinical Evaluation) and EMPIRIC trials who
et the primary prevention definition and had VT/VF
etection and therapy parameters programmed at the dis-
retion of the physician.
The MIRACLE ICD trial was a randomized study of
ardiac resynchronization therapy and ICD (Bi-V) effec-
iveness in 978 patients with New York Heart Association
unctional class II, III, or IV, left ventricular ejection
raction (LVEF) 35%, QRS duration 130 ms, and an
CD indication. Patients were enrolled from October 1999
o July 2002 and followed for a minimum of 12 months
17). The primary prevention subset of these patients (n 
15) provided the control cohort representing primary
revention patients receiving Bi-V ICD.
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August 12, 2008:541–50 The PREPARE Study Versus Physician-Tailored Programming of ICDsIn the EMPIRIC trial, 900 patients with indications for
n ICD were randomized to either standardized empiric or
hysician-tailored VT/VF programming. Patients im-
lanted with dual chamber ICDs were enrolled from Au-
ust 2002 to October 2003 and followed for 12 months.
he primary prevention subset of the physician-tailored
T/VF programmed patients from the EMPIRIC trial (n
276) provided the control cohort representing non–Bi-V
CD patients.
The control cohort was, therefore, made up of 415
rimary prevention patients from the MIRACLE ICD trial
nd 276 patients from the EMPIRIC trial, for a total of 691
atients.
rogramming. Tachyarrhythmia detection and therapy
ettings were strategically chosen in the PREPARE study
ohort to safely reduce shocks for VT/VF and SVTs
Table 1). The key strategies included: 1) detecting only fast
achycardias; 2) detecting only sustained tachycardias;
) applying ATP as first therapy for fast VTs; 4) employing
VT discriminators; and 5) employing high-output first
hock. A more detailed discussion of these strategies can be
ound in a report outlining the rationale for the study design
16). Bradycardia pacing settings were programmed at the
iscretion of the investigators. Detection and tachycardia
herapy programming changes were allowed after enroll-
ent but required documentation of medical justification.
rogramming of the VT/VF detection and therapy param-
ters in the control cohort was not specified and was at the
iscretion of the investigators.
ata collection. The PREPARE cohort patients were
ollowed for 12 months, with device interrogations and
linical evaluations at 6 and 12 months. Data collection
ncluded VT/VF and SVT episodes, device programming,
edical justifications for VT/VF programming changes,
ardiovascular medications, and cardiovascular adverse
vents. The device-detected VT/VF and SVT episodes were
lassified by the investigator and then classified by another
xpert blinded to the patients’ clinical information. Any
iscrepancies between these 2 classifications resulted in
dditional review and final classification by an electrophysi-
logist study investigator.
All cardiovascular adverse events were collected. These
vents, which included but were not limited to dizziness,
ear-syncope, and syncope, were reviewed by an adverse
vent review committee. Syncope diaries, clinical summa-
PREPARE VT/VF Programming Parameters
Table 1 PREPARE VT/VF Programming Para
Detection Threshold Beats to
VF On 250 beats/min 30 o
FVT via VF 182 beats/min 30 o
VT Monitor 167 beats/min 3
Supraventricular tachycardia criteria on (dual chamber, biventricular im
dia (1:1 VT-ST boundary  66%); supraventricular tachycardia criteria
70%); supraventricular tachycardia limit 300 ms; burst antitachycardFVT  fast ventricular tachycardia; PREPARE  Primary Prevention Param
tachycardia; VT-ST  ventricular tachycardia-sinus tachycardia.ies, and device-stored electrograms, interval plots, and
pisode logs were reviewed. If a syncopal event occurred
ithin 24 h of an arrhythmic event, it was considered related
o 1 or more VT/VF or SVT episodes.
Data collected in control patients included VT/VF and
VT episodes, device programming and justification for
T/VF programming changes, cardiovascular medications,
nd adverse events. All adverse events were reviewed and
djudicated by an adverse event review committee. Though
dverse events committees for the 3 studies were different,
ecisions for all were made by consensus of 3 to 6 physi-
ians, or, in the event no consensus was reached, a decision
as made by the committee chair. VT/VF and SVT
pisodes stored by the device were evaluated to determine if
evice detection was appropriate. The EMPIRIC trial
atients had device interrogations and clinical evaluations
erformed at 3, 6, and 12 months. The MIRACLE ICD
rial patients were evaluated at 1, 3, 6, and 12 months.
nd points. The primary end point of the study (the
orbidity index) was designed to measure not only the
eneficial effect of avoiding shocks but also to account for
he potential adverse effects of the PREPARE study ICD
rogramming. The morbidity index was comprised of the
ollowing events: 1) spontaneous episodes treated with
evice-delivered cardioversion or defibrillation, including
ppropriate and inappropriate shocks; 2) syncope secondary
o arrhythmia or presumed arrhythmia; and 3) untreated
ustained symptomatic VT/VF events (defined as untreated
ymptomatic episodes of at least 30 beats). Syncopal ar-
hythmias that were either shocked or untreated VT/VF
ere counted only once in the total number of morbidity
ndex events. The morbidity index incidence density was
alculated by dividing the morbidity index by the total
atient-years of follow-up through the first 12 months. For
he PREPARE study patients, Time 0 was the date of
rogramming to the PREPARE study VT/VF program-
ing parameters. For control patients, Time 0 was the date
f implant.
The secondary end point was the morbidity tachycardia
ndex, which was an extension of the morbidity index. The
orbidity tachycardia index was composed of 3 types of
vents evaluated in the morbidity index: 1) spontaneous
pisodes treated with device-delivered cardioversion or de-
brillation, including appropriate and inappropriate shocks;
) syncope secondary to arrhythmia or presumed arrhyth-
rs
t Therapies
30 to 35 J (max output)  6
Burst (1 sequence), 30 to 35 J (max output)  5
Off
ble cardioverter-defibrillator): atrial fibrillation/flutter, sinus tachycar-
le chamber): wavelet morphology discrimination (match threshold 
ng: 8 intervals, pacing cycle length 88% of tachycardia cycle length.mete
Detec
f 40
f 40
2
planta
on (sing
ia pacieters Evaluation study; VF  ventricular fibrillation; VT  ventricular
m
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The PREPARE Study Versus Physician-Tailored Programming of ICDs August 12, 2008:541–50ia; 3) untreated sustained symptomatic VT/VF events
defined as untreated symptomatic episodes of at least 30
eats); and also included 4) spontaneous episodes treated
nly with ATP.
tatistical analyses. Statistical analyses were performed
ccording to intention to treat and included all the
REPARE study patients and control patients with
ollow-up data. The primary hypothesis—that patients pro-
rammed using the PREPARE study parameters experience a
ower rate of morbidity index events compared with patients
rogrammed using physician-tailored programming—was
ested with a Poisson regression analysis using generalized
stimating equation methodology with an independent
orking correlation structure to account for within-patient
orrelation (18). Each patient’s outcome was the number of
vents, with patient-specific follow-up time treated as an
ffset. A propensity score analysis was used to compare
vent rates between the PREPARE study patients and
ontrol patients in 5 strata such that the PREPARE study
atients and control patients in the same stratum had
imilar distributions of baseline characteristics (19): age at
onsent, gender, device type (Bi-V ICD/non–Bi-V ICD),
aseline LVEF, use of beta-blockers, use of antiarrhythmic
gents, use of angiotensin-converting enzyme inhibitors or
ngiotensin II receptor blockers, New York Heart Associ-
tion functional classification, atrial arrhythmias, myocar-
ial infarction, valvular disease, hypertension, coronary ar-
ery bypass graft, cardiovascular syncope, and ischemic
aseline Patient Characteristics
Table 2 Baseline Patient Characteristics
PREPARE
(n  700)
Control: Bi-V ICD
(n  415)
Age, yrs, mean (SD) 67.4 (12.2) 65.4 (11.5)
Male gender 79% 75%
NYHA functional class
No heart failure or class I/II 59% 3%
Class III/IV 41% 67%
QRS duration, ms, mean (SD) 126.8 (35.4) 164.8 (22.2)
LVEF, %, mean (SD) 27.6 (10.4) 21 (6.8)
Ischemic cardiomyopathy§ 70% 57%
Myocardial infarction§ 60% 47%
Valvular heart disease§ 26% 8%
Hypertension§ 57% 44%
CABG 44% 41%
Atrial arrhythmia history¶ 33% 17%
Syncope or near-syncope# 31% 27%
Syncope 13% N/A
Baseline medications
ACE inhibitors or ARBs 84% 93%
Beta-blockers 84% 70%
Any antiarrhythmic agent 12% 23%
The MIRACLE ICD trial primary prevention patients; †the EMPIRIC trial physician-tailored, prima
omes from a t test, chi-square test, or Fisher exact test as appropriate; §1 MIRACLE ICD trial patien
sed in the calculation of percentage is 414 instead of 415; 10 patients in the MIRACLE ICD tr
enominator used in the calculation of percentages is 405 instead of 415; ¶2 MIRACLE ICD trial
enominator used in the calculation of percentages is 413 instead of 415; #1 MIRACLE ICD trial p
sed in the calculation of percentage is 414 instead of 415.
ACE  angiotensin-converting enzyme; ARB  angiotensin II receptor blocker; Bi-V  biventricular; CAB
eart Association; PREPARE  Primary Prevention Parameters Evaluation study.ardiomyopathy. Propensity scores were estimated using
ogistic regression with baseline variables and their 2-way
nteractions as covariates. The generalized estimating equa-
ion Poisson analysis was repeated within strata defined by
uintiles of the propensity score and averaged across these
trata for the propensity score-adjusted analysis of the
rimary hypothesis. Analysis of variance (ANOVA) and
ochran-Mantel-Haenszel tests were used to assess balance
f baseline covariates across quintiles of the propensity
core. Analysis of the morbidity tachycardia index was also
erformed using this methodology.
All statistical analyses were performed using SAS (version
.1, SAS Institute Inc., Cary, North Carolina). Compari-
ons of baseline characteristics were done using 2-sample t
ests and chi-square tests. Kaplan-Meier estimates with
og-rank tests and multivariable Cox proportional hazards
odels were used to compare the PREPARE study partic-
pants with the control cohort for patient mortality, all-
ause shock, shock for true VT/VF, and shock for true
VT/other.
esults
atient demographics. A total of 700 patients were en-
olled in the PREPARE study. The control cohort was
ade up of 415 primary prevention patients from the
IRACLE ICD trial and 276 patients from the
MPIRIC trial, for a total of 691 patients. There were
Control: Non–Bi-V ICD†
(n  276)
Combined Control
(n  691) p Value‡
65.6 (12) 65.5 (11.7) 0.003
80% 77% 0.3
0.06
86% 54%
14% 46%
N/A 164.8 (22.2) 0.0001
30.3 (11.0) 24.7 (9.8) 0.0001
56% 57% 0.0001
70% 56% 0.11
21% 13% 0.0001
55% 48% 0.001
49% 44% 0.98
23% 20% 0.0001
43% 33% 0.32
29% 29% 0.0001
69% 83% 0.91
76% 73% 0.0001
14% 20% 0.0001
ntion patients; ‡p value comparison of the PREPARE study cohort and combined control cohort
t complete the Cardiovascular History section of the case report form. Therefore, the denominator
ot complete the Cardiovascular Surgical History section of the case report form. Therefore, the
ts did not complete the Spontaneous Arrhythmia section of the case report form. Therefore, the
id not complete the Syncopal History section of the case report form. Therefore, the denominator*
ry preve
t did no
ial did n
patien
atient dG  coronary artery bypass grafting; LVEF  left ventricular ejection fraction; NYHA  New York
s
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August 12, 2008:541–50 The PREPARE Study Versus Physician-Tailored Programming of ICDsignificant differences in baseline characteristics between
roups (Table 2). Statistically significant differences were
vident for baseline age, LVEF, history of ischemic cardio-
yopathy, valvular heart disease, hypertension, atrial ar-
hythmias, syncope, baseline use of beta-blockers, and
aseline use of antiarrhythmic agents. A greater proportion
f patients enrolled in the PREPARE study were implanted
ith non–Bi-V ICD systems. Refer to Table 3 for details of
mplant and device characteristics. Because no record of
atients excluded from the PREPARE study for inducible
ustained VT 180 beats/min was maintained, an estimate
f patients at risk for nondetection of slow VT was derived
y finding the percentage of patients in the control cohort
ho received therapy for at least 1 VT 180 beats/min.
mong control patients, 79 of 689 (11.5%) had at least 1
pisode of VT 180 beats/min treated with ATP or shock.
Of the 700 patients, 452 (65%) received new implants at
he time of enrollment, 145 (21%) were enrolled within 30
ays of implant, and 103 (15%) were enrolled between 31
ays and 6 months after implant. Nearly all, 689 of 691
99.7%), of the control patients had follow-up data and were
ncluded in all analyses.
rogramming. Figure 1A highlights important differences
n programming between the PREPARE study patients and
ontrol patients. The PREPARE study patients were pro-
rammed according to protocol to detect and treat tachy-
ardias faster than 182 beats/min while control patients had
arying rate thresholds that were slower than 182 beats/min
or the majority of patients. Figure 1B summarizes the
umulative percentage of treated patients programmed to
TP ON. Other differences in programming at baseline
etween the PREPARE study patients and control patients
re detailed in Table 4. Of 700 PREPARE study patients
nrolled, 658 (94%) were programmed correctly to the
REPARE study VT/VF parameters during the study.
rimary end point. The morbidity index incidence density
defined as the total number of morbidity index events
ivided by the total years of follow-up in the first 12
onths) for the PREPARE study patients was significantly
ower compared with that seen in the control cohort, (0.26
s. 0.69, ratio  0.38, 95% confidence interval [CI]: 0.20 to
.72, p  0.003) (Fig. 2).
The total number of morbidity index events is adjusted
or events that count in more than 1 category. Shocked
vents and untreated VT/VF events that led to subsequent
mplant and Device Characteristics
Table 3 Implant and Device Characteristics
PREPARE (n  700) Combined Control (n  691)
Device type
Nonbiventricular 452 (65%) 276 (40%)
Single chamber 110 (24%) 0
Dual chamber 342 (76%) 276 (100%)
Biventricular 247 (35%) 415 (60%)
Unsuccessful implant 1 (1%) N/Am/A  not applicable; PREPARE  Primary Prevention Parameters Evaluation study.yncope events were counted only once in the total number
f morbidity index events. The PREPARE study patients
xperienced 178 events of which 167 were included in the
orbidity index. Not included were 11 morbidity index
vents that were not considered unique. These included 3
rrhythmic syncope events related to untreated VT/VF
vents and 8 arrhythmic syncope events related to shocked
vents. Patients in the control cohort experienced 351
orbidity index events of which 349 were included in the
orbidity index. There were 2 morbidity index events not
onsidered unique. These events were classified as arrhyth-
Figure 1 Programmed ICD Therapies Versus Heart Rate
(A) Cumulative percentage of patients programmed to antitachycardia pacing
(ATP) and/or shock therapy (number of patients with ATP or shock therapy on
at each heart rate/total number of patients in the cohort). The solid red line
illustrates that nearly all PREPARE study patients had their implantable cardio-
verter-defibrillator (ICD) enabled to treat tachycardias 182 beats/min. In con-
trast, programming for the control cohort was enabled to treat slower
tachycardias for the majority of patients. (B) Cumulative percentage of treated
patients programmed to ATP on (number of patients with ATP programmed on
at each heart rate/number of patients with ATP or shock therapy programmed
on at each heart rate). The solid red line illustrates that nearly all PREPARE
study patients who were programmed to be treated were programmed to be
treated with ATP up to 250 beats/min. In marked contrast, a large proportion
of control patients were programmed to be treated with shock, not ATP. For
example, only about 40% of control patients programmed to be treated at
heart rates faster than 200 beats/min were treated with ATP, while the remain-
ing 60% were programmed to deliver shock without ATP. Bi-V  biventricular
implantable cardioverter-defibrillator; bpm  beats/min.ic syncope and were related to shocked events.
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The PREPARE Study Versus Physician-Tailored Programming of ICDs August 12, 2008:541–50There was no evidence this result was due to imbalance in
aseline characteristics. The difference in morbidity index
ncidence density between the PREPARE study patients
nd control patients remained significant (ratio 0.44, 95%
I: 0.26 to 0.75, p  0.002) after stratifying by propensity
core quintile (Table 5). The propensity score model dis-
riminated the PREPARE study patients and control pa-
ients well (C  0.82) resulting in ANOVA and Cochran-
antel-Haenszel tests finding no imbalance of baseline
ariables between the PREPARE study participants and the
ontrol group across the 5 strata.
ICD Detection and Therapy Programming
Table 4 ICD Detection and Therapy Program
Treated rate threshold,† beats/min, median (25%, 75%)
VF number of intervals to detect, n (%)
12 of 16
18 of 24
24 of 32
30 of 40‡
SVT discriminators ON, n (%)‡
Therapy
At least 1 ATP attempt for ventricular rates, n (%)
In VT zone§
In FVT zone‡
First VF therapy, J, n (%)
20
20 to 29
30 to 35‡
*Reported values are based on 698 PREPARE study patients with av
required to be programmed with a treated rate threshold of 182 bea
parameters visit. Eight days later the patient returned for an unsched
calculation of treated rate threshold; ‡protocol-required PREPARE stu
programmed to VT monitor only.
ATP  antitachycardia pacing; ICD  implantable cardioverter-d
Table 1.
Figure 2 Morbidity Index for the PREPARE
Study Patients Versus the Control Cohort
The PREPARE study patients had fewer morbidity index events (primary end
point) as compared with the control cohort. Both appropriate and inappropriate
shocks were substantially reduced in the PREPARE study programmed patients.
There were relatively few syncopal events that contributed to the primary end
point. SVT  supraventricular tachycardia or other nonventricular tachycardia
or ventricular fibrillation event; VF  ventricular fibrillation; VT  ventricular
tachycardia. VAnalysis of the PREPARE study patients comparing
atients with a new implant at time of enrollment and those
atients with a previous implant up to 6 months before
nrollment shows that there was no difference in the
orbidity index densities between the 2 subgroups (0.24 vs.
.31, ratio  0.77, 95% CI: 0.35 to 1.69, p  0.52).
econdary end points. MORBIDITY TACHYCARDIA IN-
EX. The morbidity tachycardia index included the ad-
ition of episodes receiving only device-delivered ATP
herapy but was otherwise identical to the morbidity
ndex. The PREPARE study patients experienced 273
dditional events that received device-delivered ATP
herapy, while patients in the control cohort experienced
EPARE (n  700)* Combined Control (n  689)
182 (182, 182) 176 (162, 188)
7 (1%) 397 (58%)
4 (1%) 291 (42%)
0 1 (1%)
687 (99%) 0
690 (99%) 518 (75%)
1 (1%) 203 (29%)
693 (99%) 171 (25%)
1 (1%) 82 (12%)
10 (1%) 187 (27%)
687 (98%) 420 (61%)
baseline programming information; †PREPARE study patients were
One patient had all detection programmed OFF at the programmed
sit and therapies were turned ON. This patient is not included in the
grammed parameter; §PREPARE study patients were required to be
tor; SVT  supraventricular tachycardia; other abbreviations as in
rimary and Secondary End Pointnalyses by Propensit Score Quintile
Table 5 Primary and Secondary End PointAnalyses by Propensity Score Quintile
Quintile PREPARE Control Ratio (95% CI)
Morbidity index
1 0.30 0.84 0.35 (0.13–0.98)
2 0.20 0.89 0.23 (0.04–1.22)
3 0.39 0.46 0.85 (0.35–2.05)
4 0.28 0.42 0.66 (0.22–2.04)
5 0.20 0.54 0.37 (0.13–1.00)
Overall ratio 0.44, 95% CI: 0.26 to 0.75, p  0.002
Morbidity tachycardia index
1 0.45 2.63 0.17 (0.04–0.71)
2 0.39 2.09 0.19 (0.05–0.64)
3 0.82 0.76 1.08 (0.43–2.71)
4 1.19 2.55 0.47 (0.08–2.57)
5 0.36 1.28 0.28 (0.07–1.07)
Overall ratio 0.34, 95% CI: 0.19 to 0.62, p  0.001ming
PR
ailable
ts/min.
uled vi
dy proalues are events/patient-year.
CI  confidence interval.
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achycardia index incidence density for PREPARE pa-
ients was significantly lower than the incidence density
or the control cohort (0.70 vs. 1.96, ratio  0.36, 95%
I: 0.15 to 0.83, p  0.02). There was no evidence this
esult was due to imbalance in baseline characteristics.
Figure 3 Time to First Shock by Study Cohort
Kaplan-Meier curves show the percentage of patients (Pts) in each study cohort
receiving a first shock during the first 12 months of follow-up due to: (A) all-
cause; (B) true VT/VF; (C) true SVT/other. For each case, the p value reports
the results of a log-rank test comparing the PREPARE study cohort and control
cohort curves. Abbreviations as in Figure 2.he difference in morbidity tachycardia index incidence Vensity between the PREPARE study patients and con-
rol patients remained significant (ratio  0.34, 95% CI:
.19 to 0.62, p  0.001) after stratifying by propensity
core quintile (Table 5).
In the PREPARE study group, there were 753 episodes
f nonsustained tachycardia lasting 12 to 29 beats. Approx-
mately 290 of these were nonsustained VT based upon the
riteria of ventricular rate  atrial rate. There were 29
onitored VT episodes in addition to the 290 nonsustained
T episodes that would likely have received ATP therapy
ad these patients been programmed to treat slower, shorter
uration episodes as in the control cohort. Adding together
he 290 nonsustained VTs, 29 monitored VTs, and 273
Ts treated with ATP yields 592 slow VTs in the PRE-
ARE study patients, which is not appreciably different
han the 639 in the control cohort.
ther shock analysis. The PREPARE study patients were
ess likely to receive a shock for any cause in the first year as
ompared with the control cohort (8.5% vs. 16.9%, hazard
atio [HR]: 0.48, 95% CI: 0.34 to 0.67, p 0.01) (Fig. 3A).
his finding remained significant when controlling for
ifferences in baseline characteristics using a Cox propor-
ional hazards model (HR: 0.49, 95% CI: 0.29 to 0.82,
djusted p 0.01). The PREPARE study patients were less
ikely to receive a shock for true VT/VF in the first year as
ompared with the control cohort (5.4% vs. 9.4%, HR: 0.55,
5% CI: 0.36 to 0.84, p  0.01) (Fig. 3B), although this
nding became nonsignificant when controlling for differ-
nces in baseline characteristics (HR: 0.58, 95% CI: 0.30 to
.12, adjusted p  0.11). The PREPARE study patients
ere less likely to receive a shock for true SVT/other in the
rst year as compared with the control cohort (3.6% vs.
.5%, HR: 0.46, 95% CI: 0.28 to 0.78, p  0.01) (Fig. 3C).
his finding remained significant when controlling for
ifferences in baseline characteristics (HR: 0.38, 95% CI:
.16 to 0.86, adjusted p  0.02).
afety. Of the 290 lightheaded or syncopal adverse events
including syncope, near-syncope, and dizziness) that oc-
urred in the PREPARE study patients, 31 (11%) were
lassified as related to arrhythmia (Table 6). Of those, 15
ere judged to be related specifically to the PREPARE
tudy programming. A total of 40 true syncopal events were
eported, 12 of which were considered related to arrhythmia
nd included in the morbidity index. Of these 12, 10 were
udged to be related to the PREPARE study programming
yncopal Adverse Eventsn the PREPARE Study Patients
Table 6 Syncopal Adverse Eventsin the PREPARE Study Patients
Adverse Event
PREPARE (n  700)
Arrhythmic Nonarrhythmic Total
Syncope 11 (1.6%) 12 23 (3.3%) 28 31 (4.4%) 40
Near syncope 6 (0.9%) 6 14 (2.0%) 20 19 (2.7%) 26
Dizziness 12 (1.7%) 13 93 (13.3%) 211 101 (14.4%) 224
Total 27 (3.9%) 31 117 (16.7%) 259 131 (18.7%) 290alues are patients (%) events.
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vents, 8 completed the study and 3 withdrew from the
tudy. There were no injuries or deaths associated with these
vents. In the control cohort, cardiovascular adverse events
ere collected, but there was no systematic collection of
yncopal events. Even so, there were 4 true syncopal or
ntreated symptomatic sustained VT/VF episodes reported
n the first year of control patients’ follow-up.
Over the course of follow-up in the PREPARE cohort, 7
atients had a total of 29 monitored VT episodes with an
ncidence density of 0.046 episodes per patient-year (95%
I: 0.011 to 0.195). There was 1 reported adverse event of
izziness associated with these episodes.
The PREPARE study patients had a lower mortality rate
ompared with the control cohort (4.9% PREPARE study
atients vs. 8.7% control patients, HR: 0.55, 95% CI: 0.35,
.86, p 0.01) (Fig. 4). However, when taking into account
mbalances in baseline characteristics, the difference be-
ween study cohorts in time to mortality was not statistically
ignificant (HR: 0.57, 95% CI: 0.29 to 1.11, adjusted
 0.10).
One patient death was adjudicated as being possibly
elated to the PREPARE study programming. This patient
xperienced an episode of slow VT detected in the monitor
one that accelerated to VF and was terminated with the
ixth shock. The cause of death was determined to be
ossibly related to the prolonged ventricular arrhythmia.
iscussion
he PREPARE study programming significantly reduced
he rate of morbidity index events in primary prevention
atients when compared with the rate of events for patients
n the historical physician-tailored control cohort. Program-
ing strategies that prolong detection duration (30 of 40
Figure 4 Patient Mortality by Study Cohort
Kaplan-Meier curves show the mortality rate in patients (Pts) from each study
cohort during the first 12 months of follow-up. The p value reports the results
of a log-rank test comparing the PREPARE study cohort and control cohort
curves.aentricular beats), increase the heart rate threshold of
achycardia detection (182 beats/min), use supraventricular
etection discrimination algorithms and ATP, and encour-
ge first shock termination of tachyarrhythmias can safely
nd substantially reduce the number of tachyarrhythmias
ubjected to shock therapy.
The goal of the PREPARE study was not only to reduce
he number of treated, particularly shocked, episodes, but to
o so safely. Reducing the number of episodes subject to
herapy does not predictably reduce or improve safety.
hile slow and brief arrhythmias usually do not lead to
yncope or death, there can be slow ventricular arrhythmias
hat can cause hemodynamic compromise even with sur-
risingly brief durations (20). However, while not specifi-
ally assessed as an end point in this study, ATP and/or
hocks for sinus tachycardia or atrial fibrillation with a
elatively rapid ventricular response can themselves lead to
emodynamically compromising rhythms, ischemia, elec-
romechanical dissociation, and occasionally to syncope,
yocardial infarction, or death (21).
Overall safety in the PREPARE study was excellent as
easured by arrhythmic syncope, untreated VT, and mor-
ality. Nonarrhythmic syncopal events were common, oc-
urring in 16.7% of patients; however, arrhythmic syncope
as rare (1.6%). All-cause mortality in the PREPARE
tudy group was relatively low (Kaplan-Meier estimated
2-month mortality: 4.9%). One patient death was adjudi-
ated as possibly related to the PREPARE study program-
ing. This death followed a monitored VT lasting 1.5 min
efore accelerating into the therapy zone where 6 shocks
ere required to terminate the tachycardia. It is likely that
he patient outcome would have been no different with
ominal programming for primary prevention patients,
hich consists of a single high-rate therapy zone with or
ithout low-rate monitoring.
Historically, mortality estimates based on ICD-detected
pisodes are elevated (22). This bias is related, in part, to the
reatment of nonsustained and nonlife-threatening arrhyth-
ias before they have an opportunity to self-terminate. In
he PREPARE study, the number of sustained and treated
CD episodes probably better estimates the number of
atients that are actually rescued from death by the ICD.
he PREPARE study data clearly demonstrate that by
aiting and permitting nonsustained and slower arrhyth-
ias to self-terminate, there are fewer shocked and treated
entricular and SVTs. The magnitudes of these differences
re remarkable with the PREPARE morbidity index inci-
ence rate 38% and the morbidity tachycardia index inci-
ence rate 36% of that observed in the control cohort.
learly, the power to reduce the number of shocked and
reated tachycardias in primary prevention patients with and
ithout the need for cardiac resynchronization therapy is in
he hands of the programming physician.
The primary value of the ICD, especially in the setting of
rimary prevention, is to prolong life. However, many have
sked the question, at what cost? The cost is not just
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hich has a significant influence on patients’ and physicians’
erceptions. A programming strategy that dramatically
educes the number of painful therapies that a patient
eceives will favorably affect the perceived value of the
evice. Since the PREPARE study demonstrates that it is
ithin the physician’s control to reduce this morbidity,
hese findings are important to advancing the implementa-
ion of ICD therapy. The choice to strategically select the
rogramming of VT/VF detection and termination param-
ters, all under physician control, can make ICD therapy
ore comfortable and acceptable while still remaining safe
nd effective.
tudy limitations. The major limitation of this clinical
nvestigation was the use of a historical control cohort
nstead of a randomized control design. The considerations
n using the combination of primary prevention patients
nrolled in the MIRACLE ICD and EMPIRIC trials are
iscussed in detail in the PREPARE study design report
16). The differences in baseline characteristics between the
 groups were considerable. Antiarrhythmic agents may
low down the rate of ventricular arrhythmias and increase
he risk of underdetection of arrhythmias. Only 12% of the
REPARE study patients were treated with antiarrhythmic
gents; therefore, extrapolation of our results to patients on
ntiarrhythmic agents may not be warranted.
These differences are, in part, related to the expansion of
he primary prevention ICD indications to include patients
ithout ischemic heart disease. However, these baseline
mbalances do not appear to explain the substantial reduc-
ion in event rates based on the propensity score-adjusted
nalysis. Mortality rates were not increased in the
REPARE study patients, and although arrhythmic syn-
ope was slightly increased in the PREPARE study pa-
ients, the methodology for collecting the syncopal events in
he control cohort almost certainly underestimated the true
vent rate. Finally, it must be emphasized that the
REPARE study programming strategy was tested only
n patients without a prior history of sustained ventricular
rrhythmias. In addition, patients with induced VT
lower than 180 beats/min were excluded. Our screening
rocess did not document how many patients were
xcluded from enrollment by this exclusion criteria.
nrollment was limited to patients classified as primary
revention patients. Extrapolation of our results to pa-
ients with previously known arrhythmias before enroll-
ent is not warranted.
onclusions
trategically chosen tachycardia detection and therapy op-
ions targeting primary prevention patients can safely reduce
he morbidity related to ICD therapy. By moderately
xtending the detection duration, using fast rate cutoffs,
TP in faster rate zones, and existing SVT discriminationlgorithms, the PREPARE study programming can safely
1e used to reduce the combined morbidity of spontaneous
hocked episodes, arrhythmic syncope, and untreated sus-
ained symptomatic VT/VF events in primary prevention
atients. These same strategically chosen parameters can
lso reduce morbidity when ATP therapy is taken into
ccount and reduce the proportion of patients shocked in
he first year by all-cause, appropriate, and inappropriate
hocks. Multiple strategies were tested in aggregate to
chieve the desired result of reduced morbidity in primary
revention patients. Subsequent clinical trials are needed to
valuate the contribution of each programming component
ndependently.
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APPENDIX
or a complete list of investigators, coordinators, and institutions
articipating in the PREPARE study, please see the online version of
his article.
